Yun Kong

Prof. Dr. Yun Kong


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2020 in Microbial Cell Factories
Verified
Journal Article
Open access
PDF file
SWShengjun Wang
Shengjun Wang
YRYongheng Rong
Yongheng Rong
YWYaoguang Wang
Yaoguang Wang
DKDecai Kong
Decai Kong
PWPeng George Wang
Peng George Wang
YKYun Kong
Yun Kong
Background: Therapeutic glycoproteins have occupied an extremely important position in the market of biopharmaceuticals. N-Glycosylation of protein drugs facilitates them to maintain optimal conformations and affect their structural stabilities, serum half-lives and biological efficiencies. Thus homogeneous N-glycoproteins with defined N-glycans are essential in their application in clinic therapeutics. However, there still remain several obstacles to acquire homogeneous N-glycans, such as the high production costs induced by the universal utilization of mammalian cell expression systems, the non-humanized N-glycan structures and the N-glycosylation microheterogeneities between batches. Results: In this study, we constructed a Pichia pastoris (Komagataella phaffii) expression system producing truncated N-GlcNAc-modified recombinant proteins through introducing an ENGase isoform (Endo-T) which possesses powerful hydrolytic activities towards high-mannose type N-glycans. The results showed that the location of Endo-T in different subcellular fractions, such as Endoplasmic reticulum (ER), Golgi or cell membrane, affected their hydrolytic efficiencies. When the Endo-T was expressed in Golgi, the secreted IgG1-Fc region was efficiently produced with almost completely truncated N-glycans and the N-GlcNAc modification on the glycosite Asn297 was confirmed via Mass Spectrometry. Conclusion: This strategy develops a simple glycoengineered yeast expression system to produce N-GlcNAc modified proteins, which could be further extended to different N-glycan structures. This system would provide a prospective platform for mass production of increasing novel glycoprotein drugs.

1 February 2019 in Carbohydrate Research
Verified
Journal Article
Closed access
QMQingyun Meng
Qingyun Meng
KLKun Li
Kun Li
YRYongheng Rong
Yongheng Rong
QWQizheng Wu
Qizheng Wu
XZXunlian Zhang
Xunlian Zhang
MCMin Chen
Min Chen

16 January 2023 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
YRYongheng Rong
Yongheng Rong
XWXingyun Wang
Xingyun Wang
WMWeian Mao
Weian Mao
MCMin Chen
Min Chen
SWShengjun Wang
Shengjun Wang
YKYun Kong
Yun Kong
Herein, O -GalNAc glycosylated RBD (Tn-RBD) was synthesized as antigen via in vitro glycosylation reactions. The inhibition ability against hACE2 binding of antibodies induced with Tn-RBD was 30–40% increased.

12 September 2022 in ACS Infectious Diseases
Verified
Journal Article
Closed access
YRYongheng Rong
Yongheng Rong
XWXingyun Wang
Xingyun Wang
WMWeian Mao
Weian Mao
FYFang Yuan
Fang Yuan
MCMin Chen
Min Chen
YKYun Kong
Yun Kong

1 October 2018 in Protein Expression and Purification
Verified
Journal Article
Closed access
SWShengjun Wang
Shengjun Wang
YWYaoguang Wang
Yaoguang Wang
PWPeng George Wang
Peng George Wang
MCMin Chen
Min Chen
YKYun Kong
Yun Kong

1 September 2020 in Enzyme and Microbial Technology
Verified
Journal Article
Closed access
XZXunlian Zhang
Xunlian Zhang
WSWeihao Sheng
Weihao Sheng
KLKun Li
Kun Li
YRYongheng Rong
Yongheng Rong
QWQizheng Wu
Qizheng Wu
MCMin Chen
Min Chen